-Reuters
MacroGenics And Zai Lab Enter Collaboration To Develop And Commercialize Preclinical Bispecific Antibodies in Oncology; MacroGenics To Receive Initial Consideration Of $55M, An Equity Investment And Is Eligible For $1.4B In Milestones
Zai Lab granted combination of regional Asian and global rights for up to four CD3- or CD47-based bispecific molecules
MacroGenics provides rights to Zai Lab for its DART® and TRIDENT® multi-specific platforms